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Summary
Aims: MicroRNAs (miRNAs) are small non-coding RNAs discovered as potential new gene reg-
ulators. Their roles in the development of chronic heart failure (CHF), however, are largely
unknown. Reduced catecholamine sensitivity is an early step of CHF. We examined whether
altered expression of miRNAs was related to reduced catecholamine sensitivity in patients with
CHF.
Methods and results: Maximum ﬁrst derivative of left ventricular pressure (LV dP/dtmax) at
baseline and during infusion of dobutamine (10g kg−1 min−1) were determined in 14 asymp-
tomatic or mildly symptomatic (New York Heart Association class I or II) patients with idiopathic
dilated cardiomyopathy (DCM). We performedmicroarray analysis for a total of 485miRNAs using
endomyocardial biopsy specimens from these 14 patients. Patients were classiﬁed into 2 groups
based on a percent increase in LV dP/dtmax by dobutamine infusion (LV dP/dtmax). These are
Group I (n = 7) with LV dP/dtmax > 90%, and Group II (n = 7) with LV dP/dtmax < 90%. Out of
485 miRNAs, 32 were differentially expressed in the myocardium with reduced catecholamine
sensitivity. Among those, four miRNAs were decreased and one miRNA was increased in the
Group II compared to the Group I (p < 0.01). LVEF measured by left ventriculography at baseline
did not differ between the 2 groups. Also there were no differences in plasma norepinephrine
levels between the 2 groups.
∗ Corresponding authors. Tel.: +81 52 744 2149; fax: +81 52 744 2138.
E-mail addresses: izawa@fujita-hu.ac.jp (H. Izawa), murohara@med.nagoya-u.ac.jp (T. Murohara).
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Conclusions: Altered expression of several miRNAs was related to the reduced catecholamine
sensitivity in mildly symptomatic patients with DCM. These ﬁndings shed light on the potential
e etiologic insights as well as therapeutic targets for CHF.
ardiology. Published by Elsevier Ltd. All rights reserved.
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the mirVana miRNA Labeling Kit (Ambion). And 1× miRNA
hybridization buffer (Ambion) was added to the labeled miR-
NAs of each subject and the solution was heated to 95 ◦C forof miRNAs to provide possibl
© 2011 Japanese College of C
Introduction
Failing human heart is generally characterized by a reduced
catecholamine sensitivity that contributes to the loss of
cardiac contractility [1—3]. Previous studies demonstrated
that the reduced catecholamine sensitivity in idiopathic
dilated cardiomyopathy (DCM) patients was associated with
poor clinical prognosis [4—7]. The reduced catecholamine
sensitivity is associated with an altered myocardial gene
expression of contractile proteins even in mildly symp-
tomatic patients with DCM [8]. However, it is still unknown
what kind of molecular mechanisms regulate gene expres-
sion during the states of reduced catecholamine sensitivity.
MicroRNAs (miRNAs) are considered as one of the key reg-
ulators of gene expression [9]. MiRNAs are single-stranded
RNAs, typically with 21—24 nucleotides in length, generated
from endogenous transcripts and evolutionarily conserved
[9,10]. These small non-coding nucleotides hybridize to
mRNAs, resulting in the negative regulation of target mRNA
stability or translational inhibition of targeted transcripts
[9,10]. Although a growing body of evidence over the past
few years suggests the importance of miRNAs in oncogenesis,
neural diseases, and viral diseases [11—13], the regulatory
roles of miRNAs in the pathological process of heart failure
have only been recognized more recently [14—16].
In particular, an association of any miRNAs to the cat-
echolamine sensitivity of the heart has not yet been
examined.
We hypothesized that miRNAs could regulate and/or be
associated with the reduced catecholamine sensitivity in
the early stage of chronic heart failure (CHF). Accordingly,
we have evaluated myocardial contractility during dobu-
tamine stress testing in patients with idiopathic dilated
cardiomyopathy (DCM) and New York Heart Association
(NYHA) functional class I or II stages. We have also performed
genome-wide miRNA expression proﬁling of endomyocardial
biopsy specimens obtained from these patients.
Methods
Patients
Fourteen DCM patients with a NYHA function class I or
II with normal sinus rhythm were enrolled in the present
study. The diagnosis of DCM was based on a left ventric-
ular ejection fraction (LVEF) less than 50% as determined
by contrast ventriculography, in the absence of coronary
artery stenosis > 50% in the diameter as judged by coronary
angiography, arterial hypertension, valvular heart disease,
and cardiac muscle disease secondary to any systematic dis-
eases [17]. Endomyocardial biopsy at the right ventricular
septum was performed to exclude myocarditis or speciﬁc
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wiseases. All patients underwent laboratory measurements
ncluding echocardiography, neurohumoral factors, and car-
iac catheterization. Five patients had been treated with
eta-blockers, and nine with angiotensin-converting enzyme
nhibitors or angiotensin II receptor blockers. The Institu-
ional Ethical Review Board of Nagoya University School of
edicine approved the present study protocols including the
nalysis of miRNAs in biopsy specimens. All subjects pro-
ided written informed consent with regard to the study
rocedures, potential risks, and the analysis of miRNAs in
he biopsy specimens.
ardiac catheterization
ll patients initially underwent routine diagnostic catheteri-
ation by a radial artery approach. In brief, a 6-F ﬂuid-ﬁlled
igtail catheter with a high-ﬁdelity micromanometer (CA-
1000-PLB Pressure-tip Catheter, CD Leycom, Zoetermeer,
he Netherlands) was advanced into the LV cavity for
he measurement of LV pressure. We calculated the max-
mum ﬁrst derivative of LV pressure (LV dP/dtmax) as
n index of contractility as previously described [18,19].
fter collection of baseline hemodynamic data, dobutamine
as infused intravenously at incremental doses of 5 and
0g kg−1 min−1, and hemodynamic values were measured
t the end of each 10-min infusion period. After hemody-
amic values had returned to baseline, right ventricular
ndomyocardial biopsy was performed. At least 3 endomy-
cardial samples were obtained from the right ventricular
eptum in each patient. The biopsy samples for miRNA anal-
sis were snap frozen in liquid nitrogen and stored at −80 ◦C
ntil the analysis.
iRNA measurements and analysis
otal RNA containing miRNA was extracted from each LV
iopsy specimens using mirVana miRNA Isolation Kit accord-
ng to the manufacturer’s instruction (Ambion, Austin, TX,
SA). Quality of puriﬁed RNA was checked by capillary elec-
rophoresis (Bioanalyser 2100, Agilent Technologies, Tokyo,
apan) and then ampliﬁed by NCode miRNA Ampliﬁca-
ion System (Invitrogen, Carlsbad, CA, USA). Each puriﬁed
iRNA was labeled with the CyeDye Mono-Reactive dye
ack (GE Healthcare Bio-Science, Piscataway, NJ, USA) usingmin. Hybridization was carried out on the miRNA microar-
ay (mirVana miRNA Bioarray V9.2, Ambion) containing 485
iRNAs in quadruplicate. After hybridization, each array
as washed once with Low Stringency wash (Ambion) and
3 H. Funahashi et al.
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Figure 1 Group classiﬁcation. Patients were divided into 2
groups on the basis of the percent changes in maximum ﬁrst
d
d
v
B
B
T
t
o
g40
wice with High Stringency wash (Ambion). After the arrays
ad been centrifuged at 600× g for 3min, each sample was
canned with GenePix 4000B scanner (Axon Instruments,
nion City, CA, USA) and the signal data of each array was
alculated with an Array-Pro Analyzer Ver.4.5 (Media Cyber-
etics, Bethesda, MD, USA). The array data were normalized
y global normalization, and the quadruplicate gene data
ere averaged using Microarray Data Analysis Tool (Filgen,
ichi, Japan).
tatistical analysis
ata are presented as means± standard deviation. Statis-
ical analysis was performed by Student’s t-test. A p-value
0.05 was considered statistically signiﬁcant.
esults
atients’ classiﬁcation
atients were divided into 2 groups on the basis of the cate-
holamine sensitivity revealed by dobutamine stress testing
Fig. 1). We evaluated catecholamine sensitivity on the basis
f the percent change in LV dP/dtmax at an intravenous dobu-
amine infusion rate of 10g kg−1 min−1, with a cut-off of
0% based on the median value for patients.
Group I consisted of 7 patients whose percent changes in
−1 −1V dP/dtmax during dobutamine infusion (10g kg min )
elative to the baseline value were >90%. Group II consisted
f 7 patients whose percent changes in LV dP/dtmax dur-
ng dobutamine infusion (10g kg−1 min−1) relative to the
aseline value were <90% (Fig. 2).
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Table 1 Characteristics of the two patient groups at baseline.
Characteristic
Age (years)
Sex (M/F)
NYHA functional class (I/II)
Medication (n)
ACE inhibitors or ARBs
-blockers
LV end-diastolic dimension (mm)
LV end-systolic dimension (mm)
IVS thickness (mm)
LVPW thickness (mm)
LVEDV (ml)
LVEF (%)
LV end-diastolic pressure (mmHg)
Plasma BNP (pg/ml)
Plasma epinephrine (pg/ml)
Plasma norepinephrine (pg/ml)
Plasma dopamine (pg/ml)
Data are means± S.D.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor bloc
LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF,
wall; NYHA, New York Heart Association.erivative of left ventricular (LV) pressure dP/dtmax during
obutamine infusion (10g kg−1 min−1) relative to the baseline
alue (LV dP/dtmax).
aseline characteristics
aseline characteristics of the patients are shown in Table 1.
here were no signiﬁcant differences in clinical charac-
eristics including medications or baseline cardiac function
r plasma levels of neurohumoral factors between the 2
roups.atecholamine sensitivity revealed by dobutamine
tress test
o complications occurred during the dobutamine stress
est. The effects of intravenous dobutamine infusion on
Group I (n = 7) Group II (n = 7)
49± 14 50± 17
7/0 6/1
6/1 3/4
4 5
1 4
59± 7.2 57± 4.9
48± 9.1 48± 7.5
8.3± 1.1 8.0± 1.6
8.9± 1.3 8.0± 1.7
197± 49 220± 86
38± 12 29± 9.8
9.7± 4.8 18± 10
79± 108 450± 503
42± 23 58± 34
553± 317 1041± 974
26± 18 28± 10
ker; BNP, brain natriuretic peptide; IVS, interventricular septum;
left ventricular ejection fraction; LVPW, left ventricular posterior
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Table 2 Hemodynamic response of the two patient groups to intravenous dobutamine infusion.
Parameter Group I (n = 7) Group II (n = 7)
Heart rate (beats/min)
Baseline 74 ± 12 79 ± 15
Dobutamine (10g kg−1 min−1) 100 ± 29 99 ± 36
LVSP (mmHg)
Baseline 115 ± 31 109 ± 28
Dobutamine (10g kg−1 min−1) 147 ± 41 107 ± 14*
LV dP/dtmax (mmHg/s)
Baseline 1110 ± 309 1060 ± 183
Dobutamine (10g kg−1 min−1) 2745 ± 1209 1472 ± 339*
% Change of LV dP/dtmax from baseline 240 ± 47 138 ± 14†
Data are means± S.D.
LV dP/dtmax, maximal ﬁrst derivative of left ventricular pressure; LVSP,
* p < 0.05 versus group I.
† p < 0.01 versus group I.
hemodynamic are shown in Table 2. Heart rate both at base-
line and at a dobutamine infusion (10g kg−1 min−1) was not
signiﬁcantly different between the 2 groups. The LV systolic
pressure at baseline was not different between the 2 groups,
but that at a dobutamine infusion (10g kg−1 min−1) was sig-
niﬁcantly increased in Group I compared to Group II. There
were no signiﬁcant differences in LV dP/dtmax at baseline
between the 2 groups. However, LV dP/dtmax at a dobu-
tamine infusion (10g kg−1 min−1) was signiﬁcantly higher
in Group I than in Group II. Percent change of LV dP/dtmax at
a dobutamine infusion (10g kg−1 min−1) from baseline was
signiﬁcantly greater in Group I compared to Group II.
Differential expressions of miRNAs in patients with
reduced catecholamine sensitivity
To identify speciﬁc miRNAs with altered expression in
patients with the reduced catecholamine sensitivity, we
compared miRNA expression in the endomyocardial biopsy
4000
LV dP/dtmax(mmHg/s)
3000
*
2000
1000
0
0 5 10
Dobutamine Infusion Rate (µg/kg/min)
Figure 2 Response to dobutamine infusion. The relationship
between dobutamine infusion rate andmaximum ﬁrst derivative
of left ventricular (LV) pressure LV dP/dtmax in group I () and in
group II (©). Data are expressed as mean± SD. *p < 0.05 versus
group II.
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pecimens between the 2 groups. Out of 485 miRNAs, 32
ere differentially expressed in myocardiumwith or without
educed catecholamine sensitivity (Table 3). In particular,
ut of these 32 miRNAs, 5 were signiﬁcantly altered with p-
alue < 0.01 between the 2 groups. Expressions of 4 miRNAs,
sa-miR-323, hsa-miRNA-302d, mmu-miRNA-300, and hsa-
iRNA-10a were signiﬁcantly (p < 0.01) decreased in Group
I compared to Group I. Whereas expression of 1 miRNA, rno-
iR-422b, was signiﬁcantly (p < 0.01) increased in Group II
ompared to Group I.
iscussion
possible involvement of miRNAs in the pathological process
f CHF has recently been highlighted. In the present study,
e have shown for the ﬁrst time that 32 miRNAs were differ-
ntially expressed in cardiac tissues obtained from patients
ith early stage CHF who had reduced catecholamine sen-
itivity. In particular, the difference in the abundance of
miRNAs had critical p-value <0.01. The expressions of 4
iRNAs were decreased and the expression of 1 miRNA was
ncreased in CHF patients with reduced catecholamine sen-
itivity compared to those with preserved catecholamine
ensitivity.
educed catecholamine sensitivity in CHF
n the early stage of CHF, the adrenergic nervous activity
s stimulated due to compensatory mechanisms, supporting
he failing heart by increasing heart rate and myocar-
ial contractility. We previously showed that plasma levels
f norepinephrine were increased even in patients with
YHA functional class I or II compared to healthy subjects
8]. However, this compensatory activation of the adren-
rgic system eventually results in many adverse events
hat exacerbate the pathological process of CHF. These
nclude changes in the gene expression proﬁles of the beta1-
drenergic receptor signaling pathways, initiating reduced
atecholamine sensitivity [1,3]. Chronic activation of the
eta1-adrenergic receptor signaling pathways produces a
own-regulation of beta1-receptor expression [3], receptor
342 H. Funahashi et al.
Table 3 Mature sequence (p < 0.05).
ID Mature sequence p-Value Ratio
hsa-miR-323 GCACAUUACACGGUCGACCUCU 0.0039 0.838
hsa-miR-302d UAAGUGCUUCCAUGUUUGAGUGU 0.0061 0.832
rno-miR-422b ACUGGACUUGGAGUCAGAAGGC 0.0077 1.130
mmu-miR-300 UAUGCAAGGGCAAGCUCUCUUC 0.0087 0.824
hsa-miR-10a UACCCUGUAGAUCCGAAUUUGUG 0.0098 0.860
mmu-miR-134 UGUGACUGGUUGACCAGAGGGG 0.011 0.860
hsa-miR-378 CUCCUGACUCCAGGUCCUGUGU 0.014 1.201
mmu-miR-369-5p AGAUCGACCGUGUUAUAUUCG 0.014 1.201
hsa-miR-518e AAAGCGCUUCCCUUCAGAGUGU 0.016 1.117
mmu-miR-137 UUAUUGCUUAAGAAUACGCGUAG 0.017 1.159
hsa-miR-181a* ACCAUCGACCGUUGAUUGUACC 0.025 1.234
hsa-miR-151 ACUAGACUGAAGCUCCUUGAGG 0.026 0.859
hsa-miR-425-3p AUCGGGAAUGUCGUGUCCGCC 0.026 1.159
hsa-miR-99a AACCCGUAGAUCCGAUCUUGUG 0.027 0.829
hsa-miR-148b UCAGUGCAUCACAGAACUUUGU 0.028 0.896
hsa-miR-212 UAACAGUCUCCAGUCACGGCC 0.030 1.127
hsa-miR-520d AAAGUGCUUCUCUUUGGUGGGUU 0.032 1.155
mmu-miR-451 AAACCGUUACCAUUACUGAGUU 0.036 0.846
hsa-miR-202 AGAGGUAUAGGGCAUGGGAAAA 0.036 0.839
hsa-miR-302a* UAAACGUGGAUGUACUUGCUUU 0.038 0.869
hsa-miR-205 UCCUUCAUUCCACCGGAGUCUG 0.039 1.214
hsa-miR-376b AUCAUAGAGGAAAAUCCAUGUU 0.040 0.910
hsa-miR-325 CCUAGUAGGUGUCCAGUAAGUGU 0.040 1.123
hsa-miR-134 UGUGACUGGUUGACCAGAGGG 0.043 0.879
rno-miR-207 GCUUCUCCUGGCUCUCCUCCCUU 0.043 0.927
hsa-miR-505 GUCAACACUUGCUGGUUUCCUC 0.045 1.186
hsa-miR-204 UUCCCUUUGUCAUCCUAUGCCU 0.045 1.154
hsa-miR-29c UAGCACCAUUUGAAAUCGGU 0.045 1.375
hsa-miR-142-5p CAUAAAGUAGAAAGCACUAC 0.046 0.903
hsa-miR-384 AUUCCUAGAAAUUGUUCAUA 0.048 1.134
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ncoupling, and an increase in the expression of G-protein-
oupled receptor kinase 2 and of the alpha subunit of Gi2
20,21]. Thus, CHF is characterized by altered expressions
f the beta1-adrenergic receptor signaling pathways, which
s believed to account for the reduced catecholamine sensi-
ivity. However, it is still unclear as to whether the reduced
atecholamine sensitivity in CHF is mediated by any genetic
egulatory mechanisms.
Although several studies have begun focusing on miR-
As in the pathogenesis of CHF, published studies thus far
nvestigated the expression of miRNAs only in the condi-
ion of cardiac hypertrophy and reduced contractility in
nimal models or in the end-stage human failing heart
14—16,22]. To the best of our knowledge, here we report for
he ﬁrst time that 32 miRNAs were differentially expressed
n myocardium of asymptomatic or mildly symptomatic
atients with reduced catecholamine sensitivity.peciﬁc miRNAs related to the reduced
atecholamine sensitivity
ut of 32 miRNAs whose expression levels were altered in
he myocardium with the reduced catecholamine sensitivity,
b
m
a
o
[UUC 0.048 1.117
UGU 0.048 1.235
he expression of 4 miRNAs (miR-10, miR-300, miR-302, and
iR-323) were signiﬁcantly decreased and the expression
f 1 miRNA (miR-422) was signiﬁcantly increased compared
o the myocardium with preserved catecholamine sensi-
ivity. The most signiﬁcantly down-regulated miRNA was
iR-323. It has been shown that miR-323 is correlated with
he karyotype in primary adult acute myeloid leukemia.
romyelocytic leukemias bearing the t(15; 17) translocation
ere characterized by the up-regulation of miR-323 tran-
cribed from genes located at the 14q32 region, suggesting
he potential role of miR-323 in the etiology of leukemia
23]. MiR-302 is also expressed abundantly in slow-growing
uman embryonic stem cells and quickly decreased after cell
ifferentiation and proliferation, which has been thought
o be a key molecule in attenuating the global produc-
ion of developmental signals and/or transcription factors
24]. MiR-302 is also over expressed in malignant germ cell
umors and coordinately down-regulates mRNAs involved in
iologically signiﬁcant pathways [25]. MiR-10 was found to
e down-regulated in all types of leukemia carrying the
ajor translocation events, associated with a more favor-
ble prognosis [26]. A recent report showed down-regulation
f miR-10a in the lungs of rats exposed to cigarette smoke
27]. Any functional roles of miR-300 or 422 have not been
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reported so far, and all these 5 miRNAs identiﬁed differently
expressed in the current study have never been implicated
in cardiac pathophysiology. However, as mentioned above,
these miRNAs have been reported to possess regulatory
roles in the embryonic as well as postnatal processes, such
as cell proliferation, cell cycle, and cell differentiation.
These ﬁndings provide compelling evidence of the possi-
ble involvement of miRNAs in the pathological alterations of
intracellular signaling pathways. Many previous clinical trials
proved that beta1-adrenergic receptor antagonists result in
reserve remodeling and reduce morbidity and mortality, and
that beta1-adrenergic receptor signaling pathways play an
important role in the progression of human heart failure. We
previously demonstrated that reduced catecholamine sensi-
tivity could be associated with altered expression of proteins
related to beta1-adrenergic receptor signaling pathways [8].
Then, these 5 signiﬁcant miRNAs in the present study, could
be involved in the altered beta1-adrenergic receptor sig-
naling pathways, which could induce myocardial contractile
dysfunction in failing hearts. However, it is still uncertain
whether these 5 miRNAs directly affect the alterations of
functional proteins related to the beta1-adrenergic recep-
tor signaling pathways. The contribution of these miRNAs to
the altered beta1-adrenergic receptor signaling pathways is
still speculative, and further studies should be needed to
clarify this hypothesis.
Study limitations
One limitation of the present study is the small size of the
study population. However, we applied higher level of statis-
tical rigor to identify speciﬁc miRNAs in this study, accepting
only results that were statistically signiﬁcant (p < 0.01).
However, due to our small sample size, it is possible that
we may have underestimated or overestimated miRNAs.
Second, we did not evaluate the expressions of miRNAs
associated with medications or catecholamine sensitivity by
quantitative polymerase chain reaction or Northern blot in
this study because it is difﬁcult to withdraw drugs and to
obtain large amount of myocardial tissues from patients for
ethical reasons. We also could not evaluate the exact cell
source of miRNA expression in the endomyocardial tissues
because of very small samples. A future larger scale study
would be required to conﬁrm and expand our current ﬁnd-
ings.
Conclusions
Knowledge of genetic regulatory mechanisms for reduced
catecholamine sensitivity in the early stage of CHF is
essential for understanding pathophysiology of CHF, and ulti-
mately for establishing the treatment strategies for CHF.
In the present study, we newly identiﬁed a set of 5 miR-
NAs that represent the reduced catecholamine sensitivity in
asymptomatic or mildly symptomatic patients with CHF. Our
ﬁndings suggest that these miRNAs may have key regulatory
roles in the beta1-adrenergic pathway and shed light on the
future possibility of miRNAs as potential therapeutic targets
in CHF.
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